Baird Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target to $875
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice TargetHot
Baird analyst Brian Skorney maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and raises the price target from $761 to $875.
Baird analyst Brian Skorney maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and raises the price target from $761 to $875.